Rossi Jean-François
Department of Hematology, University Hospital, CHU Saint Eloi, 80 avenue Augustin Fliche, 34295 Montpellier Cedex 05, France ; Université Montpellier I, UFR Médecine, 34396 Montpellier, France.
Biomed Res Int. 2015;2015:217593. doi: 10.1155/2015/217593. Epub 2015 Sep 6.
B-lymphocytes are programmed for the production of immunoglobulin (Ig) after antigen presentation, in the context of T-lymphocyte control within lymphoid organs. During this differentiation/activation process, B-lymphocytes exhibit different restricted or common surface markers, activation of cellular pathways that regulate cell cycle, metabolism, proteasome activity, and protein synthesis. All molecules involved in these different cellular mechanisms are potent therapeutic targets. Nowadays, due to the progress of the biology, more and more targeted drugs are identified, a situation that is correlated with an extended field of the targeted therapy. The full knowledge of the cellular machinery and cell-cell communication allows making the best choice to treat patients, in the context of personalized medicine. Also, focus should not be restricted to the immediate effects observed as clinical endpoints, that is, response rate, survival markers with conventional statistical methods, but it should consider the prediction of different clinical consequences due to other collateral drug targets, based on new methodologies. This means that new reflection and new bioclinical follow-up have to be monitored, particularly with the new drugs used with success in B-cell malignancies. This review discussed the principal aspects of such evident bioclinical progress.
在淋巴器官内T淋巴细胞的控制下，B淋巴细胞在抗原呈递后被编程用于产生免疫球蛋白（Ig）。在这个分化/激活过程中，B淋巴细胞表现出不同的限制性或共同的表面标志物，以及调节细胞周期、代谢、蛋白酶体活性和蛋白质合成的细胞途径的激活。参与这些不同细胞机制的所有分子都是有效的治疗靶点。如今，由于生物学的进展，越来越多的靶向药物被发现，这种情况与靶向治疗领域的扩展相关。对细胞机制和细胞间通讯的全面了解有助于在个性化医疗的背景下为治疗患者做出最佳选择。此外，关注点不应局限于作为临床终点观察到的直接效果，即采用传统统计方法的缓解率、生存标志物，而应基于新方法考虑由于其他附带药物靶点导致的不同临床后果的预测。这意味着必须监测新的思考和新的生物临床随访，特别是对于在B细胞恶性肿瘤中成功使用的新药。本综述讨论了这种明显的生物临床进展的主要方面。
